数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Uri Yablonka Director, EVP, Chief Business Officer and Secretary 46 7.79万美元 未持股 2023-11-08
Anthony Polverino Director 61 2.46万美元 未持股 2023-11-08
Jacob Frenkel Chairperson and Director 80 15.28万美元 未持股 2023-11-08
Menghisteab Bairu Director 63 未披露 未持股 2023-11-08
Nir Naor Director 49 未披露 未持股 2023-11-08
Irit Arbel Vice-Chairperson and Director 62 14.80万美元 未持股 2023-11-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Uri Yablonka Director, EVP, Chief Business Officer and Secretary 46 7.79万美元 未持股 2023-11-08
Alla Patlis Interim Chief Financial Officer and Controller 36 8.00万美元 未持股 2023-11-08
Stacy Lindborg Co-Chief Executive Officer 53 85.15万美元 未持股 2023-11-08
Chaim Lebovits Chief Executive Officer 52 111.80万美元 未持股 2023-11-08

董事简历

中英对照 |  中文 |  英文
Uri Yablonka

Uri Yablonka于2014年6月6日加入该公司,担任其首席运营官与董事。加入该公司前,Yablonka先生从2010年12月开始担任Uri Yablonka Ltd.的股东与总经理,这是一家商业咨询公司。他还从2011年1月开始担任ACC International Holdings Ltd.(Holdings)的业务开发部的副总裁。Holdings还是ACCBT Corp.的附属公司,在Holdings供职前,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人。从2008年到2011年1月,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人,他在PM-PR Media Consulting Ltd.领导了范围广泛的政府与私人机构的公共关系与战略咨询业务。从2002年到2008年,他担任Maariv Daily News Paper的通讯记者,包括担任外交通讯记者提供的丰富服务。


Uri Yablonka,joined the Company on June 6, 2014 as Chief Operating Officer and as a director. On March 6, 2017 he was appointed Executive Vice President, Chief Business Officer and ceased to serve as the Company's Chief Operating Officer. Prior to joining the Company, beginning in 2010, Mr. Yablonka served as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. From January 2011 to May 2014, he served as Vice President, Business Development at ACC International, an affiliate of ACCBT. Prior to his role in ACC International, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. from 2008 to January 2011, where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. Mr. Yablonka holds an LL.B from Ono Academic College and an LL.M from Bar-Ilan University, and is a member of the Israeli Bar Association.
Uri Yablonka于2014年6月6日加入该公司,担任其首席运营官与董事。加入该公司前,Yablonka先生从2010年12月开始担任Uri Yablonka Ltd.的股东与总经理,这是一家商业咨询公司。他还从2011年1月开始担任ACC International Holdings Ltd.(Holdings)的业务开发部的副总裁。Holdings还是ACCBT Corp.的附属公司,在Holdings供职前,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人。从2008年到2011年1月,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人,他在PM-PR Media Consulting Ltd.领导了范围广泛的政府与私人机构的公共关系与战略咨询业务。从2002年到2008年,他担任Maariv Daily News Paper的通讯记者,包括担任外交通讯记者提供的丰富服务。
Uri Yablonka,joined the Company on June 6, 2014 as Chief Operating Officer and as a director. On March 6, 2017 he was appointed Executive Vice President, Chief Business Officer and ceased to serve as the Company's Chief Operating Officer. Prior to joining the Company, beginning in 2010, Mr. Yablonka served as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. From January 2011 to May 2014, he served as Vice President, Business Development at ACC International, an affiliate of ACCBT. Prior to his role in ACC International, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. from 2008 to January 2011, where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. Mr. Yablonka holds an LL.B from Ono Academic College and an LL.M from Bar-Ilan University, and is a member of the Israeli Bar Association.
Anthony Polverino

Anthony Polverino于2018年2月5日加入公司,担任董事。Polverino博士目前担任ZymeworksInc.早期开发执行Vice President兼首席科学官,他于2018年9月加入该公司,负责制定愿景和战略,和组织的一般管理,并监督产品从发现研究到转化研究/早期开发的进展,以创建与临床开发的无缝链接。在Zymeworks之前,Polverino博士是Kite(现为Gilead Sciences的全资子公司)的临时首席科学官,他于2015年加入该公司,负责建立Kite的战略性非临床研发路线图,以支持其当前和未来的投资组合。此前,他曾担任Kite公司的研究Vice President,在那里他的职责包括公司目标设定、预算分配、科学和投资者互动、业务发展许可和伙伴关系交易。Polverino博士在Amgen,Inc.担任了20年的职责递增的职位,最近担任其治疗创新单元的执行董事,在那里他管理肿瘤学,代谢性疾病,炎症性疾病和精神分裂症的研究计划。任职Amgen公司之前,他曾担任Cold Spring Harbor Laboratory的博士后科学家,在那里他主要从事肿瘤学研究。Polverino博士是多项专利的作者,并在近40家科学和同行评审期刊上发表过文章。他获得了理学学士学位。生物化学/生理学学士学位和理学学士学位(荣誉)药理学学位,均来自澳大利亚阿德莱德的阿德莱德大学(Adelaide University),以及同样位于阿德莱德的弗林德斯大学(Flinders University)的生物化学博士学位。


Anthony Polverino,joined the Company on February 5, 2018 as a director. Dr. Polverino is currently an independent consultant to corporate executives and board members. Dr. Polverino was an Executive Vice President Early Development and Chief Scientific Officer of Zymeworks Inc. ("Zymeworks") from September of 2018 to January 2022, and where he was responsible for establishing the vision, strategy, and general management of the organization and overseeing the advancement of products from discovery research through translational research/early development to create a seamless link to clinical development. Prior to Zymeworks, Dr. Polverino was the interim Chief Scientific Officer of Kite Pharma, Inc. ("Kite") (now a wholly-owned subsidiary of Gilead Sciences), which he joined in 2015, and where he was responsible for establishing Kite's strategic non-clinical R&D roadmap to support its current and future portfolio. Prior to this, he was the Vice President of research at Kite, where his responsibilities included corporate goal setting, budget allocation, scientific and investor interactions, business development in-licensing and partnership deals. Dr. Polverino spent 20 years in positions of increasing responsibilities at Amgen, Inc. ("Amgen"), most recently as executive director of its Therapeutic Innovation Unit, where he managed research programs in oncology, metabolic disease, inflammatory disease and schizophrenia. Prior to Amgen, he was a postdoctoral scientist at Cold Spring Harbor Laboratory, where he worked primarily on oncology research. He earned a B.Sc. in Biochemistry/Physiology and a B.Sc. (Honors) in Pharmacology, both from Adelaide University in Adelaide, Australia and a Ph.D. in Biochemistry from Flinders University, also in Adelaide.
Anthony Polverino于2018年2月5日加入公司,担任董事。Polverino博士目前担任ZymeworksInc.早期开发执行Vice President兼首席科学官,他于2018年9月加入该公司,负责制定愿景和战略,和组织的一般管理,并监督产品从发现研究到转化研究/早期开发的进展,以创建与临床开发的无缝链接。在Zymeworks之前,Polverino博士是Kite(现为Gilead Sciences的全资子公司)的临时首席科学官,他于2015年加入该公司,负责建立Kite的战略性非临床研发路线图,以支持其当前和未来的投资组合。此前,他曾担任Kite公司的研究Vice President,在那里他的职责包括公司目标设定、预算分配、科学和投资者互动、业务发展许可和伙伴关系交易。Polverino博士在Amgen,Inc.担任了20年的职责递增的职位,最近担任其治疗创新单元的执行董事,在那里他管理肿瘤学,代谢性疾病,炎症性疾病和精神分裂症的研究计划。任职Amgen公司之前,他曾担任Cold Spring Harbor Laboratory的博士后科学家,在那里他主要从事肿瘤学研究。Polverino博士是多项专利的作者,并在近40家科学和同行评审期刊上发表过文章。他获得了理学学士学位。生物化学/生理学学士学位和理学学士学位(荣誉)药理学学位,均来自澳大利亚阿德莱德的阿德莱德大学(Adelaide University),以及同样位于阿德莱德的弗林德斯大学(Flinders University)的生物化学博士学位。
Anthony Polverino,joined the Company on February 5, 2018 as a director. Dr. Polverino is currently an independent consultant to corporate executives and board members. Dr. Polverino was an Executive Vice President Early Development and Chief Scientific Officer of Zymeworks Inc. ("Zymeworks") from September of 2018 to January 2022, and where he was responsible for establishing the vision, strategy, and general management of the organization and overseeing the advancement of products from discovery research through translational research/early development to create a seamless link to clinical development. Prior to Zymeworks, Dr. Polverino was the interim Chief Scientific Officer of Kite Pharma, Inc. ("Kite") (now a wholly-owned subsidiary of Gilead Sciences), which he joined in 2015, and where he was responsible for establishing Kite's strategic non-clinical R&D roadmap to support its current and future portfolio. Prior to this, he was the Vice President of research at Kite, where his responsibilities included corporate goal setting, budget allocation, scientific and investor interactions, business development in-licensing and partnership deals. Dr. Polverino spent 20 years in positions of increasing responsibilities at Amgen, Inc. ("Amgen"), most recently as executive director of its Therapeutic Innovation Unit, where he managed research programs in oncology, metabolic disease, inflammatory disease and schizophrenia. Prior to Amgen, he was a postdoctoral scientist at Cold Spring Harbor Laboratory, where he worked primarily on oncology research. He earned a B.Sc. in Biochemistry/Physiology and a B.Sc. (Honors) in Pharmacology, both from Adelaide University in Adelaide, Australia and a Ph.D. in Biochemistry from Flinders University, also in Adelaide.
Jacob Frenkel

Jacob Frenkel于2020年3月加入公司,担任董事兼董事长。Frenkel博士担任三十国集团(Group of Three)的董事会主席,该集团是一家国际经济和货币事务的私人非营利咨询集团。Frenkel博士于2009年至2020年担任摩根大通国际董事长,目前担任摩根大通高级顾问。从2001年到2011年,他担任G-30的主席兼首席执行官,从2004年到2009年担任美国国际集团公司的副主席,从2000年到2004年担任美林国际的主席。从1991年到2000年,他曾担任以色列银行(Bank of Israel)的两届行长。他担任特拉维夫大学(Tel Aviv University)的董事会主席,在那里他也是the Frenkel-Zuckerman Institute for Global Economics的主席。他持有耶路撒冷希伯来大学(the Hebrew University of Jerusalem)的经济学和政治学学士学位,以及芝加哥大学(the University of Chicago)的经济学硕士和博士学位。


Jacob Frenkel,joined the Company in March 2020 as a director and Chairprson. Dr. Frenkel serves as Chairman of the Board of Trustees of the Group of Thirty, which is a private, nonprofit, Consultative Group on International Economic and Monetary Affairs. Dr. Frenkel served as Chairman of JPMorgan Chase International from 2009 to 2020 and is currently serving as a Senior Advisor to JPMorgan Chase. From 2001 to 2011 he served as Chairman and Chief Executive Officer of the G-30, from 2004 to 2009 as Vice Chairman of American International Group, Inc., and from 2000 to 2004 as Chairman of Merrill Lynch International. Between 1991 and 2000 he served two terms as the Governor of the Bank of Israel. Dr. Frenkel serves as Chairman of the Board of Governors of Tel Aviv University, where he is also Chairman of the Frenkel-Zuckerman Institute for Global Economics. He holds a B.A. in economics and political science from the Hebrew University of Jerusalem, and an M.A. and Ph.D. in economics from the University of Chicago.
Jacob Frenkel于2020年3月加入公司,担任董事兼董事长。Frenkel博士担任三十国集团(Group of Three)的董事会主席,该集团是一家国际经济和货币事务的私人非营利咨询集团。Frenkel博士于2009年至2020年担任摩根大通国际董事长,目前担任摩根大通高级顾问。从2001年到2011年,他担任G-30的主席兼首席执行官,从2004年到2009年担任美国国际集团公司的副主席,从2000年到2004年担任美林国际的主席。从1991年到2000年,他曾担任以色列银行(Bank of Israel)的两届行长。他担任特拉维夫大学(Tel Aviv University)的董事会主席,在那里他也是the Frenkel-Zuckerman Institute for Global Economics的主席。他持有耶路撒冷希伯来大学(the Hebrew University of Jerusalem)的经济学和政治学学士学位,以及芝加哥大学(the University of Chicago)的经济学硕士和博士学位。
Jacob Frenkel,joined the Company in March 2020 as a director and Chairprson. Dr. Frenkel serves as Chairman of the Board of Trustees of the Group of Thirty, which is a private, nonprofit, Consultative Group on International Economic and Monetary Affairs. Dr. Frenkel served as Chairman of JPMorgan Chase International from 2009 to 2020 and is currently serving as a Senior Advisor to JPMorgan Chase. From 2001 to 2011 he served as Chairman and Chief Executive Officer of the G-30, from 2004 to 2009 as Vice Chairman of American International Group, Inc., and from 2000 to 2004 as Chairman of Merrill Lynch International. Between 1991 and 2000 he served two terms as the Governor of the Bank of Israel. Dr. Frenkel serves as Chairman of the Board of Governors of Tel Aviv University, where he is also Chairman of the Frenkel-Zuckerman Institute for Global Economics. He holds a B.A. in economics and political science from the Hebrew University of Jerusalem, and an M.A. and Ph.D. in economics from the University of Chicago.
Menghisteab Bairu

Menghisteab Bairu于2021年10月加入公司,担任董事。自2016年12月以来,Bairu博士一直担任Proxenia Venture Partners的创始人兼董事长兼首席执行官,该公司专注于生物技术的临床前后期和早期临床开发。自2018年12月以来,Bairu博士还担任Bairex的董事长兼首席执行官,该公司是一家专注于非洲和中东地区的国际医学教育和市场研究机构。Bairu博士还于2016年至2019年担任Treos Bio Limited的执行主席,该公司是一家初创公司,利用计算生物学开发针对患者遗传学的精密癌症免疫疗法。此外,他是Serenus Biothericals,Inc.(一家专注于新兴市场的专业生物制药公司)的创始人兼名誉主席,自2013年以来一直在其董事会任职。Bairu博士在米兰大学获得医学博士学位,目前担任加州大学旧金山分校医学院的兼职教授,在那里他讲授全球临床试验的设计,开发和行为。


Menghisteab Bairu,joined the Company in October 2021 as a director. Since December 2016, Dr. Bairu has served as the founder, chairman and Chief Executive Officer of Proxenia Venture Partners,which focuses on companies in late preclinical and early-stage clinical development in biotechnology. Dr. Bairu has also served as Chairman and Chief Executive Officer of Bairex, an international medical education and market research organization focused on Africa and the Middle East since December 2018. Dr. Bairu also served as Executive Chairman of Treos Bio Limited from 2016 to 2019, a start-up company that Brainstorm Cell Therapeutics Inc. es computational biology to develop precision cancer immunotherapies tailored to patients' genetics. In addition, he is Founder and Chairman Emeritus of Serenus Biotherapeutics, Inc., an emerging market focused specialty biopharmaceutical company, and has served on its board since 2013. Dr. Bairu received his M.D. from Università degli Studi di Milano and currently serves as Adjunct Professor at the University of California, San Francisco School of Medicine, where he lectures on global clinical trials' design, development, and conduct.
Menghisteab Bairu于2021年10月加入公司,担任董事。自2016年12月以来,Bairu博士一直担任Proxenia Venture Partners的创始人兼董事长兼首席执行官,该公司专注于生物技术的临床前后期和早期临床开发。自2018年12月以来,Bairu博士还担任Bairex的董事长兼首席执行官,该公司是一家专注于非洲和中东地区的国际医学教育和市场研究机构。Bairu博士还于2016年至2019年担任Treos Bio Limited的执行主席,该公司是一家初创公司,利用计算生物学开发针对患者遗传学的精密癌症免疫疗法。此外,他是Serenus Biothericals,Inc.(一家专注于新兴市场的专业生物制药公司)的创始人兼名誉主席,自2013年以来一直在其董事会任职。Bairu博士在米兰大学获得医学博士学位,目前担任加州大学旧金山分校医学院的兼职教授,在那里他讲授全球临床试验的设计,开发和行为。
Menghisteab Bairu,joined the Company in October 2021 as a director. Since December 2016, Dr. Bairu has served as the founder, chairman and Chief Executive Officer of Proxenia Venture Partners,which focuses on companies in late preclinical and early-stage clinical development in biotechnology. Dr. Bairu has also served as Chairman and Chief Executive Officer of Bairex, an international medical education and market research organization focused on Africa and the Middle East since December 2018. Dr. Bairu also served as Executive Chairman of Treos Bio Limited from 2016 to 2019, a start-up company that Brainstorm Cell Therapeutics Inc. es computational biology to develop precision cancer immunotherapies tailored to patients' genetics. In addition, he is Founder and Chairman Emeritus of Serenus Biotherapeutics, Inc., an emerging market focused specialty biopharmaceutical company, and has served on its board since 2013. Dr. Bairu received his M.D. from Università degli Studi di Milano and currently serves as Adjunct Professor at the University of California, San Francisco School of Medicine, where he lectures on global clinical trials' design, development, and conduct.
Nir Naor

Nir Naor于2023年6月加入公司,担任董事和审计委员会主席。Naor先生一直担任一些私营公司的财务顾问。Naor先生于2023年2月至2023年9月担任QuVa Pharma的首席财务官。Naor先生曾于2021年12月至2022年10月担任HMNC Brain Health的首席财务官,并于2021年1月至2021年9月担任Arbor Pharmaceuticals的首席财务官。在此之前,Naor先生于2017年10月至2021年1月担任Molnlycke美国和美洲首席财务官。在此之前,Naor先生于2016年7月至2017年7月担任UCB美国首席财务官。此前,纳奥尔在生物制药行业担任过多个高级财务领导职务。此前,纳奥尔曾在以色列担任投资银行家和商业律师。Naor先生是注册会计师(以色列,非在职)和特许金融分析师,拥有瑞士IMD商学院的MBA学位和以色列特拉维夫大学的MBA学位,德国汉堡大学的法学硕士学位,以及以色列特拉维夫大学的法学学士学位和会计学学士学位。


Nir Naor,joined the Company in June 2023 as a director and as Chair of the Audit Committee. Mr. Naor has been serving in a finance advisory capacity to a number of private companies. Mr. Naor served as Chief Financial Officer of QuVa Pharma from February 2023 to September 2023. Mr. Naor previously served as the Chief Financial Officer of HMNC Brain Health from December 2021 to October 2022 and as the Chief Financial Officer of Arbor Pharmaceuticals from January 2021 to September 2021. Prior to this, Mr. Naor served as the Chief Financial Officer, U.S. and the Americas, of Molnlycke, from October 2017 to January 2021. Prior to this, Mr. Naor served as Chief Financial Officer, U.S., of UCB from July 2016 to July 2017. Previously, Mr. Naor held various senior leadership finance roles in the biopharmaceutical industry. Previously, Mr. Naor worked as an investment banker and as a commercial lawyer in Israel. Mr. Naor is a Certified Public Accountant (Israel, inactive) and a Chartered Financial Analyst, and holds an MBA from IMD Business School in Switzerland and an MBA from Tel Aviv University in Israel, an L.L.M. from Hamburg University in Germany, and an L.L.B. in Law and a Bachelor degree in Accounting from Tel Aviv University in Israel.
Nir Naor于2023年6月加入公司,担任董事和审计委员会主席。Naor先生一直担任一些私营公司的财务顾问。Naor先生于2023年2月至2023年9月担任QuVa Pharma的首席财务官。Naor先生曾于2021年12月至2022年10月担任HMNC Brain Health的首席财务官,并于2021年1月至2021年9月担任Arbor Pharmaceuticals的首席财务官。在此之前,Naor先生于2017年10月至2021年1月担任Molnlycke美国和美洲首席财务官。在此之前,Naor先生于2016年7月至2017年7月担任UCB美国首席财务官。此前,纳奥尔在生物制药行业担任过多个高级财务领导职务。此前,纳奥尔曾在以色列担任投资银行家和商业律师。Naor先生是注册会计师(以色列,非在职)和特许金融分析师,拥有瑞士IMD商学院的MBA学位和以色列特拉维夫大学的MBA学位,德国汉堡大学的法学硕士学位,以及以色列特拉维夫大学的法学学士学位和会计学学士学位。
Nir Naor,joined the Company in June 2023 as a director and as Chair of the Audit Committee. Mr. Naor has been serving in a finance advisory capacity to a number of private companies. Mr. Naor served as Chief Financial Officer of QuVa Pharma from February 2023 to September 2023. Mr. Naor previously served as the Chief Financial Officer of HMNC Brain Health from December 2021 to October 2022 and as the Chief Financial Officer of Arbor Pharmaceuticals from January 2021 to September 2021. Prior to this, Mr. Naor served as the Chief Financial Officer, U.S. and the Americas, of Molnlycke, from October 2017 to January 2021. Prior to this, Mr. Naor served as Chief Financial Officer, U.S., of UCB from July 2016 to July 2017. Previously, Mr. Naor held various senior leadership finance roles in the biopharmaceutical industry. Previously, Mr. Naor worked as an investment banker and as a commercial lawyer in Israel. Mr. Naor is a Certified Public Accountant (Israel, inactive) and a Chartered Financial Analyst, and holds an MBA from IMD Business School in Switzerland and an MBA from Tel Aviv University in Israel, an L.L.M. from Hamburg University in Germany, and an L.L.B. in Law and a Bachelor degree in Accounting from Tel Aviv University in Israel.
Irit Arbel

Irit Arbel, 头脑风暴的共同创建人,2004年5月年以董事的身份加入公司,并担任了6个月的总裁。目前,她是治理、提名和薪酬委员会的主席。从2012年7月开始,她是Savicell Diagnostic Ltd.研究与开发部的执行副总裁。Savicell Diagnostic Ltd.是一家生物技术公司,是 Online Disruptive Technologies, Inc的全资子公司。从2009年到2011年,她是Real Aesthetics Ltd.,(一家脂肪团超声波治疗,BRH医疗和伤口愈合医疗设备的开发的公司)的主席。她也是RFB投资公司,(一家关注相关公司早期技术的私人投资公司)的董事。以前,她是 Pluristem Life Systems,(一家生物技术公司的总裁和首席执行官)。在这之前,她是 Merck, Sharp & Dohme,(一家制药公司的以色列销售经理)。1997年,她进行微生物学博士后多发性硬化症的研究。她也从 Technion,以色列的技术学院获得化学工程学位。


Irit Arbel,one of the Company's co-founders, joined the Company in May 2004 as a director and served as President of the Company for six months. Currently, Dr. Arbel is the Vice-Chairperson of the Board and the Chair of the Governance, Nominating and Compensation Committee. She previously served as Chief Executive Officer of Neurochords Corp ("Neurochords"), a biotechnology firm developing graphene-based scaffolds for nerve reconstruction in the acute spinal cord and peripheral nerve injury, from August 2018 to 2020. Prior to Neurochords, Dr. Arbel served as Executive Vice President, Research and Development at Savicell Diagnostic Ltd from July 2012 until August 2018. From 2009 through 2011, Dr. Arbel served as Chairperson of Real Aesthetics Ltd., a company specializing in cellulite ultrasound treatment, and BRH Medical, a developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early stage technology related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, Inc., a biotechnology company, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel's Institute of Technology.
Irit Arbel, 头脑风暴的共同创建人,2004年5月年以董事的身份加入公司,并担任了6个月的总裁。目前,她是治理、提名和薪酬委员会的主席。从2012年7月开始,她是Savicell Diagnostic Ltd.研究与开发部的执行副总裁。Savicell Diagnostic Ltd.是一家生物技术公司,是 Online Disruptive Technologies, Inc的全资子公司。从2009年到2011年,她是Real Aesthetics Ltd.,(一家脂肪团超声波治疗,BRH医疗和伤口愈合医疗设备的开发的公司)的主席。她也是RFB投资公司,(一家关注相关公司早期技术的私人投资公司)的董事。以前,她是 Pluristem Life Systems,(一家生物技术公司的总裁和首席执行官)。在这之前,她是 Merck, Sharp & Dohme,(一家制药公司的以色列销售经理)。1997年,她进行微生物学博士后多发性硬化症的研究。她也从 Technion,以色列的技术学院获得化学工程学位。
Irit Arbel,one of the Company's co-founders, joined the Company in May 2004 as a director and served as President of the Company for six months. Currently, Dr. Arbel is the Vice-Chairperson of the Board and the Chair of the Governance, Nominating and Compensation Committee. She previously served as Chief Executive Officer of Neurochords Corp ("Neurochords"), a biotechnology firm developing graphene-based scaffolds for nerve reconstruction in the acute spinal cord and peripheral nerve injury, from August 2018 to 2020. Prior to Neurochords, Dr. Arbel served as Executive Vice President, Research and Development at Savicell Diagnostic Ltd from July 2012 until August 2018. From 2009 through 2011, Dr. Arbel served as Chairperson of Real Aesthetics Ltd., a company specializing in cellulite ultrasound treatment, and BRH Medical, a developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early stage technology related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, Inc., a biotechnology company, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel's Institute of Technology.

高管简历

中英对照 |  中文 |  英文
Uri Yablonka

Uri Yablonka于2014年6月6日加入该公司,担任其首席运营官与董事。加入该公司前,Yablonka先生从2010年12月开始担任Uri Yablonka Ltd.的股东与总经理,这是一家商业咨询公司。他还从2011年1月开始担任ACC International Holdings Ltd.(Holdings)的业务开发部的副总裁。Holdings还是ACCBT Corp.的附属公司,在Holdings供职前,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人。从2008年到2011年1月,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人,他在PM-PR Media Consulting Ltd.领导了范围广泛的政府与私人机构的公共关系与战略咨询业务。从2002到2008年,他担任Maariv Daily News Paper的通讯记者,包括担任外交通讯记者提供的丰富服务。


Uri Yablonka,joined the Company on June 6, 2014 as Chief Operating Officer and as a director. On March 6, 2017 he was appointed Executive Vice President, Chief Business Officer and ceased to serve as the Company's Chief Operating Officer. Prior to joining the Company, beginning in 2010, Mr. Yablonka served as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. From January 2011 to May 2014, he served as Vice President, Business Development at ACC International, an affiliate of ACCBT. Prior to his role in ACC International, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. from 2008 to January 2011, where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. Mr. Yablonka holds an LL.B from Ono Academic College and an LL.M from Bar-Ilan University, and is a member of the Israeli Bar Association.
Uri Yablonka于2014年6月6日加入该公司,担任其首席运营官与董事。加入该公司前,Yablonka先生从2010年12月开始担任Uri Yablonka Ltd.的股东与总经理,这是一家商业咨询公司。他还从2011年1月开始担任ACC International Holdings Ltd.(Holdings)的业务开发部的副总裁。Holdings还是ACCBT Corp.的附属公司,在Holdings供职前,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人。从2008年到2011年1月,Yablonka先生担任PM-PR Media Consulting Ltd.的高级合伙人,他在PM-PR Media Consulting Ltd.领导了范围广泛的政府与私人机构的公共关系与战略咨询业务。从2002到2008年,他担任Maariv Daily News Paper的通讯记者,包括担任外交通讯记者提供的丰富服务。
Uri Yablonka,joined the Company on June 6, 2014 as Chief Operating Officer and as a director. On March 6, 2017 he was appointed Executive Vice President, Chief Business Officer and ceased to serve as the Company's Chief Operating Officer. Prior to joining the Company, beginning in 2010, Mr. Yablonka served as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. From January 2011 to May 2014, he served as Vice President, Business Development at ACC International, an affiliate of ACCBT. Prior to his role in ACC International, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. from 2008 to January 2011, where he led public relations and strategy consulting for a wide range of governmental and private organizations. From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent. Mr. Yablonka holds an LL.B from Ono Academic College and an LL.M from Bar-Ilan University, and is a member of the Israeli Bar Association.
Alla Patlis

Alla Patlis,她于2012年12月23日加入公司,担任总会计师。她于2015年5月13日被任命为临时首席财务官,期间公司寻找一个新首席财务官。加入公司之前(从2010年到2012年12月),她曾担任Brightman Almagor Zohar公司的科技、媒体和电信行业的高级审计师、注册会计师,以及Deloitte Touche Tohmatsu Limited公司的成员。她持有Tel Aviv University的工商管理硕士学位、会计和经济学士学位。


Alla Patlis,joined the Company in December 2012 as Controller. From May 2015 to July 2015, November 2016 to November 2017, July 2019 to September 2019 and September 2021 to present, the Company appointed Ms. Patlis as its Interim Chief Financial Officer during the search for a new Chief Financial Officer, and she currently serves in that capacity. Prior to joinin the Company, from 2010 to December 2012, Ms. Patlis was Audit Senior of technology, media and telecommunications industries at Brightman Almagor Zohar & Co. (Certified Public Accountants, A Member of Deloitte Touche Tohmatsu Limited). Ms. Patlis holds an MBA and a Bachelor's degree in Accounting & Economics from Tel Aviv University.
Alla Patlis,她于2012年12月23日加入公司,担任总会计师。她于2015年5月13日被任命为临时首席财务官,期间公司寻找一个新首席财务官。加入公司之前(从2010年到2012年12月),她曾担任Brightman Almagor Zohar公司的科技、媒体和电信行业的高级审计师、注册会计师,以及Deloitte Touche Tohmatsu Limited公司的成员。她持有Tel Aviv University的工商管理硕士学位、会计和经济学士学位。
Alla Patlis,joined the Company in December 2012 as Controller. From May 2015 to July 2015, November 2016 to November 2017, July 2019 to September 2019 and September 2021 to present, the Company appointed Ms. Patlis as its Interim Chief Financial Officer during the search for a new Chief Financial Officer, and she currently serves in that capacity. Prior to joinin the Company, from 2010 to December 2012, Ms. Patlis was Audit Senior of technology, media and telecommunications industries at Brightman Almagor Zohar & Co. (Certified Public Accountants, A Member of Deloitte Touche Tohmatsu Limited). Ms. Patlis holds an MBA and a Bachelor's degree in Accounting & Economics from Tel Aviv University.
Stacy Lindborg

Stacy Lindborg于2020年6月1日在Executive Vice President加入公司,担任全球临床研究主管。Lindborg博士是一位经验丰富的梦百合执行官和全球公认的医学统计学家,在研发、监管、战略发展、分析和大数据方面拥有20多年的跨国经验。她的经验包括在Eli Lilly&Company和Biogen担任高级职务。林德伯格博士于2012年至2020年在BiogenInc.任职,最近担任Vice President、分析和数据科学。她也曾任职Biogen公司的研发治理团队,期间曾任职Biogen公司,也曾积极指导公司的长期增长愿景(通过分析和刺激创新开发平台以提高生产力)。她的团队推动了新颖的分析和开发方法,这些方法在物质上为Spinraza®;和Aducanumab®;等产品做出了贡献。在Eli Lilly&Company,她担任职责递增的职位,包括研发战略主管,在那里她负责表征投资组合的生产力并推动包括年度研发长期计划在内的关键研发战略项目。在这个职位上,她通过将基于单个药物计划的开发决策与投资组合风险实践联系起来,创造了对研发生产力的开创性见解,推动了基本的研发决策,以增加药物发布的数量。此外,她曾担任Zyprexa Product Management公司的领导,在那里她负责研发、商业和制造计划。她负责通过产品差异化,全球注册和推出Zyprexa的注射形式来推动市场份额,通过监管制造检查和483次引用来工作。Lindborg博士拥有Baylor University统计学博士学位。


Stacy Lindborg,has served as Brainstorm Cell Therapeutics Inc. Co-Chief Executive Officer since January 2023. Prior to this, from June 2020 to January 2023, Dr. Lindborg served as Brainstorm Cell Therapeutics Inc. Executive Vice President and Chief Development Officer. She currently serves on the board of directors of Imunon, Inc. (formerly Celsion Corporation), a publicly-traded clinical stage biotechnology company. Dr. Lindborg previously served at Biogen Inc. ("Biogen") from 2012 to 2020, where she was most recently Vice President, Analytics and Data Science. She also served on the R&D governance team during a time of significant growth for Biogen, and was active in guiding the firm's long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. Prior to her role at Biogen, Dr. Lindborg worked at Eli Lilly & Company, where she held positions of increasing responsibility. In her role as the Head of R&D strategy, she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. Dr. Lindborg holds a Ph.D. in statistics from Baylor University.
Stacy Lindborg于2020年6月1日在Executive Vice President加入公司,担任全球临床研究主管。Lindborg博士是一位经验丰富的梦百合执行官和全球公认的医学统计学家,在研发、监管、战略发展、分析和大数据方面拥有20多年的跨国经验。她的经验包括在Eli Lilly&Company和Biogen担任高级职务。林德伯格博士于2012年至2020年在BiogenInc.任职,最近担任Vice President、分析和数据科学。她也曾任职Biogen公司的研发治理团队,期间曾任职Biogen公司,也曾积极指导公司的长期增长愿景(通过分析和刺激创新开发平台以提高生产力)。她的团队推动了新颖的分析和开发方法,这些方法在物质上为Spinraza®;和Aducanumab®;等产品做出了贡献。在Eli Lilly&Company,她担任职责递增的职位,包括研发战略主管,在那里她负责表征投资组合的生产力并推动包括年度研发长期计划在内的关键研发战略项目。在这个职位上,她通过将基于单个药物计划的开发决策与投资组合风险实践联系起来,创造了对研发生产力的开创性见解,推动了基本的研发决策,以增加药物发布的数量。此外,她曾担任Zyprexa Product Management公司的领导,在那里她负责研发、商业和制造计划。她负责通过产品差异化,全球注册和推出Zyprexa的注射形式来推动市场份额,通过监管制造检查和483次引用来工作。Lindborg博士拥有Baylor University统计学博士学位。
Stacy Lindborg,has served as Brainstorm Cell Therapeutics Inc. Co-Chief Executive Officer since January 2023. Prior to this, from June 2020 to January 2023, Dr. Lindborg served as Brainstorm Cell Therapeutics Inc. Executive Vice President and Chief Development Officer. She currently serves on the board of directors of Imunon, Inc. (formerly Celsion Corporation), a publicly-traded clinical stage biotechnology company. Dr. Lindborg previously served at Biogen Inc. ("Biogen") from 2012 to 2020, where she was most recently Vice President, Analytics and Data Science. She also served on the R&D governance team during a time of significant growth for Biogen, and was active in guiding the firm's long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. Prior to her role at Biogen, Dr. Lindborg worked at Eli Lilly & Company, where she held positions of increasing responsibility. In her role as the Head of R&D strategy, she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. Dr. Lindborg holds a Ph.D. in statistics from Baylor University.
Chaim Lebovits

Chaim Lebovits,他于2007年7月加入公司。他管理ACC HOLDINGS INTERNATIONAL和其子公司ACC Resources(专门从事矿业、石油和能源产业)和ACC BioTech(专注于生物技术)。他一直在西非和以色列的前沿继续拧矿业和自然资源管理超过10年,他领导在西非和以色列的资源的勘探和开发。他还担任几个行业私人公司的董事会成员。他也担任全球 Chabad Lubavitch organization(当今世界上最大的犹太组织)的高级职务。


Chaim Lebovits,has served as Brainstorm Cell Therapeutics Inc. Chief Executive Officer since September of 2015, and has served as Brainstorm Cell Therapeutics Inc. President since January 2023. Mr. Lebovits joined the Company as President in connection with his arrangement of an equity investment by ACC BioTech in the Company in July 2007. On August 1, 2013, the Company appointed Mr. Lebovits as its Principal Executive Officer, and he assumed the duties and responsibilities of the Chief Executive Officer on an interim basis until June 2014. During his tenure with the Company, Mr. Lebovits has been instrumental in the various capital raises undertaken by the Company and in his capacity as President Mr. Lebovits managed relatively low burn rates and was very instrumental in the major decisions of the Company's focus and direction, including the decision to focus on Amyotrophic Lateral Sclerosis ("ALS", also known as Lou Gehrig's Disease) as a first indication. Mr. Lebovits led efforts to attract the clinical sites first in Israel and later in the United States, building strong relationships for the Company with many leading Key Opinion Leaders and Centers of Excellence for ALS in the United States. Mr. Lebovits controls ACC Holdings International, and its subsidiaries including ACC BioTech, which is focused on the biotechnology sector. He has been at the forefront of natural resource management and has spent years leading the exploration and development of resources in Israel and served as a member of the boards of directors of several companies in the industry. Mr. Lebovits has also held senior positions for the worldwide Chabad Lubavitch organization, the largest Jewish organization in the world today.
Chaim Lebovits,他于2007年7月加入公司。他管理ACC HOLDINGS INTERNATIONAL和其子公司ACC Resources(专门从事矿业、石油和能源产业)和ACC BioTech(专注于生物技术)。他一直在西非和以色列的前沿继续拧矿业和自然资源管理超过10年,他领导在西非和以色列的资源的勘探和开发。他还担任几个行业私人公司的董事会成员。他也担任全球 Chabad Lubavitch organization(当今世界上最大的犹太组织)的高级职务。
Chaim Lebovits,has served as Brainstorm Cell Therapeutics Inc. Chief Executive Officer since September of 2015, and has served as Brainstorm Cell Therapeutics Inc. President since January 2023. Mr. Lebovits joined the Company as President in connection with his arrangement of an equity investment by ACC BioTech in the Company in July 2007. On August 1, 2013, the Company appointed Mr. Lebovits as its Principal Executive Officer, and he assumed the duties and responsibilities of the Chief Executive Officer on an interim basis until June 2014. During his tenure with the Company, Mr. Lebovits has been instrumental in the various capital raises undertaken by the Company and in his capacity as President Mr. Lebovits managed relatively low burn rates and was very instrumental in the major decisions of the Company's focus and direction, including the decision to focus on Amyotrophic Lateral Sclerosis ("ALS", also known as Lou Gehrig's Disease) as a first indication. Mr. Lebovits led efforts to attract the clinical sites first in Israel and later in the United States, building strong relationships for the Company with many leading Key Opinion Leaders and Centers of Excellence for ALS in the United States. Mr. Lebovits controls ACC Holdings International, and its subsidiaries including ACC BioTech, which is focused on the biotechnology sector. He has been at the forefront of natural resource management and has spent years leading the exploration and development of resources in Israel and served as a member of the boards of directors of several companies in the industry. Mr. Lebovits has also held senior positions for the worldwide Chabad Lubavitch organization, the largest Jewish organization in the world today.